Table 1.

Patient Clinical and Demographic Information

Demographics and clinical variables	Control	n-3 PUFA	p-value
Total n	12	12	—
Age (years)	63.1±8.4	65.8±9.9	0.81
Female sex, n (%)	3 (25)	5 (42)	0.41
Race (C/AA)	9/3	11/1	0.3
BMI	32.0±7.8	30.2±7.0	0.61
HbA1c	5.9±0.8	6.1±1.6	0.67
HDL	40.2±11.8	41.0±13.1	0.89
LDL	105.9±38.9	88.1±26.2	0.22
Triglycerides	170.8±62.9	136.1±43.2	0.14
LVEF (%)	55.8±7.6	57.3±6.8	0.64
Hypertension, n (%)	9 (75)	9 (75)	1
Diabetes, n (%)	2 (16)	3 (25)	0.63
Intraoperative characteristics
CABG only, n (%)	7 (47)	6 (50)	0.7
CABG+Valve repair/replace, n (%)	2 (16)	3 (25)	0.63
Valve repair/replace, n (%)	3 (25)	3 (25)	1
CPB Time (min)	98.5±20.0	101.1±17.2	0.74
Cross-clamp time (min)	86.1±18.1	87.8±14.1	0.8
Preoperative medications–N (%)
Aspirin	9 (75)	10 (83)	0.78
β-Blocker	10 (83)	10 (83)	1
Anti-depressant	1 (8)	2 (16)	0.56
Statin	3 (25)	2 (16)	0.63
Calcium channel blocker	1 (8)	1 (8)	1
ACE Inhibitor/ARB	8 (66)	5 (42)	0.24
Insulin	1 (8)	1 (8)	1
Biguanides	0	1 (8)	0.69
Postoperative events
Postoperative AF	4 (33)	2 (16)	0.37
Hospitalization LOS (days)	7.4±3.4	6.6±2.9	0.53
Inotropic Support	2 (16)	1 (8)	0.56
Other Complications, n (%)	1 (8)	2 (16)	0.56

Values for continuous variables expressed as mean±SD. Tests of statistical significance were performed using unpaired Student's t-test for continuous variables, or Fisher's exact test for categorical variables. C, Caucasian; AA, African American; BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; CPB, cardiopulmonary bypass; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AF, atrial fibrillation; LOS, length of stay.